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2 TESCH ET ALBackground: Recent findings strongly support hematopoietic
stem cell transplantation (HSCT) in patients with severe
presentation of LPS-responsive beige-like anchor protein
(LRBA) deficiency, but long-term follow-up and survival data
beyond previous patient reports or meta-reviews are scarce for
those patients who do not receive a transplant.
Objective: This international retrospective study was conducted
to elucidate the longitudinal clinical course of patients with
LRBA deficiency who do and do not receive a transplant.
Method: We assessed disease burden and treatment responses
with a specially developed immune deficiency and dysregulation
activity score, reflecting the sum and severity of organ
involvement and infections, days of hospitalization, supportive
care requirements, and performance indices.
Results: Of 76 patients with LRBA deficiency from 29 centers
(median follow-up, 10 years; range, 1-52), 24 underwent HSCT
from 2005 to 2019. The overall survival rate after HSCT
(median follow-up, 20 months) was 70.8% (17 of 24 patients); all
deaths were due to nonspecific, early, transplant-related
mortality. Currently, 82.7% of patients who did not receive a
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partial remission without treatment (together, 12 of 17 [70.6%]).
In contrast, only 5 of 43 patients who did not receive a
transplant (11.6%) are without immunosuppression. Immune
deficiency and dysregulation activity scores were significantly
lower in patients who survived HSCT than in those receiving
conventional treatment (P 5 .005) or in patients who received
abatacept or sirolimus as compared with other therapies, and in
patients with residual LRBA expression. Higher disease burden,
longer duration before HSCT, and lung involvement were
associated with poor outcome.
Conclusion: The lifelong disease activity, implying a need for
immunosuppression and risk of malignancy, must be weighed
against the risks of HSCT. (J Allergy Clin Immunol
2020;nnn:nnn-nnn.)
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first described in 2012,1 is a severe primary immunodeficiency
with a broad spectrum of clinical and immunologic manifesta-
tions caused by biallelic mutations in the LRBA gene.2-6 LRBA
is ubiquitously expressed and involved in signal transduction, ve-
sicular trafficking, autophagy, and apoptosis; abolished expres-
sion may impair key processes related to immunity.1,7,8 LRBA
normally prevents cytotoxic T-lymphocyte protein-4 (CTLA4)
from lysosomal degradation by bringing it back to the cell sur-
face; its absence leads to decreased CTLA4 expression.9 The re-
sulting regulatory T (Treg)-cell defect causes immune
dysregulation and autoimmunity, the symptoms of which partially
resemble those of CTLA4 insufficiency (see Fig E1 in this arti-
cle’s Online Repository at www.jacionline.org).2,4-6,10-13
Until recently, the conventional treatment options for LRBA
deficiency have included various immunosuppressive agents,
such as corticosteroids, sirolimus, and abatacept (a soluble
CTLA4 immunoglobulin fusion protein that appears to partially
restore Treg-cell function).5,6,9 One prospective study14 andatient cohort characteristics of 76 patients with LRBA d
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nvolvement, yes/no Yes 5others9,15-19 reported on the effectiveness of the latter. However,
soluble CTLA4 might not fully replace membrane-bound
CTLA4 or other LRBA functions. Thus, the use of purely conven-
tional treatment options might not prevent the long-term deterio-
ration of patients with LRBA deficiency.8 Furthermore, risks
associatedwith the need for continuous immunosuppressive treat-
ment (eg, immunosuppression-associated infection or malig-
nancy) remain.8 Earlier studies reported that most patients with
LRBA deficiency who have undergone hematopoietic stem cell
transplantation (HSCT) achieved complete remission; however,
the studies also detected higher transplant-related mortality
(TRM) rates than have been seen in patients with other inborn er-
rors of immunity.5,8,20 No genotype-phenotype correlation has
been detected,2,4,5 but milder phenotypes with residual protein
expression have been observed. Thus, doctors treating patients
with LRBA deficiency need more information regarding whether
and when to proceed with HSCT.
This international, retrospective study was conducted to
broaden our knowledge of the transplant experience and chart
the clinical course of patients with LRBA deficiency undergoing
various targeted treatment modalities who did and did not receive
a transplant. In addition, we assessed the disease activity and
treatment responses by using a specially developed immune
deficiency and dysregulation activity (IDDA) scoring method,
which might also be useful in the management of patients with
other combined immunodeficiencies with immune dysregulation.METHODS
We performed an international European Society for Blood and Marrow
Transplantation Inborn Errors and Clinical Working Parties and European
Society for Immunodeficiencies Registry Working Party–wide retrospective
multicenter study. Pseudonymized data were obtained by retrospective chart
review with the patient’s informed consent according to Good Clinical
Practice guidelines and institutional review board approvals (IRB00002556,eficiency under conventional treatment or after HSCT
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FIG 1. Survival status of a retrospective cohort of 76 patients with LRBA deficiency. A, At the time of anal-
ysis, 60 of 76 reported patients with LRBA deficiency, who had been followed for 1 to 52 years (median: 10
years), were alive. B, The outcome and remission status of patients with LRBA deficiency after HSCT is
shown as complete remission (CR); good partial remission (GPR), indicating that some clinical symptoms
potentially related to LRBA deficiency were still detectable but did not require immunosuppressive treat-
ment; PR, indicating patients who had residual autoimmune symptoms that were treated; or death. All
deaths were due to TRM. C, Of 52 patients receiving conventional, pharmacologic immunosuppression,
43 were alive. D, Of the 24 patients who received a transplant, 17 were alive at the time of analysis.
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4 TESCH ET AL24-334 ex 11/12, and 29-142ex16/17) from May 2018 to May 2019 (see the
SupplementaryMaterial in this article’s Online Repository at www.jacionline.
org).RESULTS
Baseline characteristics, clinical presentation, and
overall survival
A total of 76 patients with a genetically confirmed diagnosis of
LRBA deficiency (39 of whomwere hitherto unreported) from 29
centers were included (42 females, 34 males; Table I and see
Table E1 in this article’s Online Repository at www.jacionline.
org). Of the 76 patients, 24 (31.6%) had undergone HSCT and
47 (61.8%) had received only immunosuppressive therapy. Five
patients (6.6%), aged 5, 8, 11, 21, and 37 years, did not require
immunosuppressive treatment and presented with either mild
symptoms (lymphopenia, thrombocytopenia, urinary tract infec-
tion) or were asymptomatic and identified through family
screening. In all, 60 patients (78.9%) were still living at the
time of the analysis (43 of 52 [82.7%] conventionally treated
and 17 of 24 [70.8%] patients who had undergone HSCT; Table
I and Fig 1, A, C, D). The median age at disease onset was 2 years
(range, birth-25 years; Table I). HSCT survivors showed a favor-
able degree of remission, as 70.6% were currently without treat-
ment (Fig 1, B), whereas 88.4% of the patients who did not
undergo HSCT needed treatment at the time of analysis. Themedian follow-up after the onset of symptomswas 9.4 years in pa-
tients who had undergone HSCT (range, 1-21) versus 10 years
(range, 1-52) in conventionally treated patients. The median cur-
rent age of HSCT survivors and living patients under conventional
treatment was 13 years (ranges, 3-23 and 3-69, respectively).
The probability of survival 15 to 20 years after disease onset
was around 50% to 60% in both treatment cohorts (Fig 2, A), but
this number might be misleading on account of the variable time
points of initiation and modalities of treatment. Therefore, we
compared the survival probability rates after HSCTwith the rates
after the introduction of pharmacologic immunosuppression (Fig
2, B). We observed that all post-HSCT deaths occurred within the
first 3 months after HSCT. In contrast, the risk of mortality re-
mained constant in patients who received conventional treatment
(Fig 2, B), who also had an increased disease burden compared
with that of HSCT survivors, as measured by organ involvement,
performance in daily activities, and the intensity of the required
care (see later; Fig 2,C). The causes of death are listed in Table II.
The frequency distribution of clinical findings was similar to
that reported by previous studies (see the Supplementary
Material). Of note, malignancies occurred in 3 patients (3.9%).
One patient developed gastric cancer (at age 19 years) and malig-
nant melanoma (at age 27 years); both cancers were surgically
treated.21 Malignancies of the central nervous system (CNS), an
astrocytic tumor and a CNS lymphoma, were reported in 2 pa-
tients. Remarkably, all 16 deceased patients—7 who received a
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FIG 2. Survival probabilities of 76 patients with LRBA deficiency under various treatment modalities. The
survival probability of patients receiving conventional treatment (blue) versus HSCT (red) is shown as a per-
centage in years from disease onset (A) or years from introduction of immunosuppression (IS) or after trans-
plantation (post-HSCT) (B). C, The latest reported disease activity, as evaluated by the IDDA scoringmethod,
is shown with median error and SE (P 5 0.005). D, For 24 patients who had undergone HSCT, the overall
survival (OS) probability according to the year of transplantation is shown. E, The OS according to the
time elapsed from onset of symptoms until performance of HSCT is shown. F, The OS of 16 patients after
HSCT is shown according to their pre-HSCT IDDA score. G, The OS from disease onset is shown for all 76
patients with LRBA deficiency who did or did not have lung involvement (with 95% confidence intervals in
[G] and [H]). H, The OS of 12 patients with reduced is shown along with the OS of 39 patients with absent
(undetectable) protein expression. I, The average disease burden (IDDA score) of patients with residual or
absent LRBA expression is shown with median error and SE (P 5 .017; IDDA scores of patients after HSCT
were excluded).
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TESCH ET AL 5transplant and 9 who did not—suffered from lung involvement
(lymphocytic interstitial pneumonia, granulomatous-
lymphocytic interstitial lung disease, or other parenchymal lung
disease; Fig 2, G); the cause of death included respiratory failure
or severe lung infections in 10 of these 16 patients (62.5%; Table
II). The overall survival probability was significantly lower in pa-
tients with lung involvement than in patients without (P5 .002);
to date, all the patients with LRBA deficiency without lung
involvement are alive, whereas 16 of the 41 patients with lung
involvement (39%) have died (Fig 2, G). Furthermore, the multi-
variate analysis results showed that lung involvement (P 5 .008)
and autoimmune cytopenia (P 5 .017) significantly correlated
with a fatal disease outcome in LRBA deficiency (including all
the organ systems involved in LRBA deficiency that are listed
in Table III22,23). Other findings that were observed either before
HSCT or before conventional treatment did not significantly
correlate with the outcome. The residual expression of LRBAprotein was intriguingly associated with a 100% survival rate,
whereas 9 of 39 patients (23.1%) with absent protein expression
died (n 5 51, Fig 2, H; P 5 .071). Disease burden was signifi-
cantly lower in patients with residual LRBA expression as
compared with in those without it (Fig 2, I; P 5 .017).Characteristics and courses of patients with LRBA
deficiency undergoing HSCT
A total of 24 patients with LRBA deficiency, 8 of whom were
previously unreported, underwent HSCT between 2005 and 2019
(see Table E2 in this article’s Online Repository at www.
jacionline.org). The median time that elapsed between the onset
of symptoms and the transplantation procedure was 7.4 years
(range, 0.4-15.8 years; Table I). Indications for HSCT included
recurrent severe infections, refractory immune cytopenia (eg,
Evans syndrome), chronic parenchymal lung disease, severe
TABLE II. Causes of 16 deaths among 76 patients with LRBA deficiency
Patient no. Age at death
Time interval after
onset of symptoms
Time interval after
genetic diagnosis
Time interval
after HSCT Cause of death
6 25y 15.5 y 1.5 y 13 d Sepsis, respiratory failure
10 9 y 8.5 y After death 2 mo MOF
13 10 y 5.5 y After death 2 mo Nonengraftment, MOF
16 14 y 13 y After death 3.5 mo Refractory GvHD, multiple infections
19 12 y 9 y 2.5 y 3 mo Invasive pulmonary aspergillosis
20 6 y 3 y n.a. 3 mo Respiratory failure, lung fibrosis, adenovirus
pneumonia, graft rejection
22 10 y 6 y 10 mo 2 mo Adenoviremia, thrombotic microangiopathy, pneumonitis
25 17 y 15 y 1 y — Cardiac and renal failure
26 19 y 17 y After death — Respiratory failure
27 11 y 8 y After death — Respiratory failure
32 22 y 19 y 1 y — Respiratory failure
35 20 mo 14 mo 2 mo — CNS hemorrhage
39 15 y 13 y 2 y — Respiratory and renal failure
41 20 y 12 y After death — Respiratory and renal failure
54 14 y n.a. n.a. — Severe lung infection
73 35 y 35 y 3 y — Respiratory failure
n.a., Not available; MOF, multiorgan failure; GvHD, graft versus host disease.
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6 TESCH ET ALgastrointestinal problems, failure to thrive, severe autoimmunity,
and severe neurologic complications (see Table E2).
The overall survival rate of patients undergoing HSCT was
70.8% (17 of 24 patients; Fig 1, B andC). All 7 deaths were due to
early TRM (graft failure, multiorgan failure, preexisting severe
infections, refractory acute graft-versus-host disease, or throm-
botic microangiopathy; Table II). Of the 17 surviving patients,
7 were in complete remission, 5 were in good partial remission
(PR) (with some mild or moderate, potentially LRBA-related
symptoms not requiring immunosuppressive treatment), and 5
were in PR (with amelioration of the disease, but in need of immu-
nosuppressive treatment for potentially LRBA-related symptoms;
Fig 1, B). Thus, 70.6% of patients (12 of 17) who survived HSCT
are currently without treatment. Furthermore, the performance
scores increased, and the need for immunoglobulin replacement
therapy decreased in all HSCT survivors (see Fig E2 in this arti-
cle’s Online Repository at www.jacionline.org). The mean
follow-up time for the 17 surviving patients was 36.2 months
(range, 3-171). Nine patients (37.5%) developed acute graft-
versus-host disease (see Table E2; skin, grade I-II in 6 patients;
gastrointestinal, grade II in 1; and gastrointestinal grade IV in
3). Ten of 11 patients (all in complete remission or with a good
PR) for whom information was available had full donor chime-
rism (>95% donor white blood cells [WBCs]). We identified a
positive association between full donor chimerism and the most
favorable degrees of remission after HSCT. Graft failure was
observed in 2 patients (8.3%). Patient 13 had 0% donor WBCs
on day 130 and died 2 months after HSCT as a result of poor
engraftment and sepsis. Patient 10 had 71% donor WBCs on
day 130, followed by a total loss of graft on day 175, and died
2 months after the second transplantation as a result of multiorgan
failure. The overall survival rates were significantly better in pa-
tients who underwent HSCTwithin the first 3 years after the onset
of LRBA-related symptoms than in individuals with a longer dis-
ease duration (P 5 .0001; Fig 2, E). HSCT course and outcome
were not dependent on the donors’ LRBA carrier status, condi-
tioning regimen, donor type, or age at HSCT (see Table E2),
although a trend toward better survival rates in younger patients
and those with lower disease activity scores (see later and Fig 2,F) was detected. In addition, survival of HSCT was associated
with the transplantation year (Fig 2, D), although these data
were not statistically significant (P 5 .13): Since 2015, only 1
of 10 patients (10%) who underwent HSCT has died, but up until
2015, the rate of TRMwas 42.9% (6 of 14 patients who received a
transplant).IDDA score
We developed a special IDDA score that allowed us to conduct
intraindividual, longitudinal monitoring and assess the interindi-
vidual disease burden carried by patients with LRBA deficiency.
The score includes an assessment of organ involvement (graded
0-4, depending on the severity and need for treatment), which was
weighted by performance indices. This weighted score was added
to the score for days of hospitalization, the need for intensive or
supportive care, and the number of infections (for details, see
Table III). The IDDA score was assessed in 16 patients who had
undergone HSCT (13 of whom are alive at the time of writing
this publication) and in 51 patients who received conventional
therapy. This assessment was conducted retrospectively at multi-
ple time points (median 2, range, 1-10) to allow a longitudinal
evaluation to be made (Fig 3).
The median IDDA score of the patients before HSCT was
32.9 (range, 7.7-108.6); this score was significantly higher than
in patients receiving conventional treatment (median 20.8; P 5
.006). The IDDA score decreased significantly in all surviving
patients after transplantation (P 5 .005, see Figs 3, B and 4,
C). The latest median IDDA score obtained from HSCT survi-
vors was 6.3 (range, 0-29.5, Table I and Fig 2, C). The pre-
HSCT IDDA scores of the 3 patients who died and for
whom data were available were 18.7, 28.8, and 102.5.
A lower pre-HSCT IDDA score was associated with a better
survival probability, as beginning HSCT with an IDDA score
below 15 (n 5 3) was correlated with an overall survival
rate of 100%, whereas overall survival decreased in patients
with higher pre-HSCT scores, although these data were not
statistically significant on account of the small sample
size (Fig 2, F). Furthermore, organ-specific, LRBA
TABLE III. IDDA score and data of the present cohort
Parameter (use score 0-4)*
Gradey
0, n (%) I, n (%) II, n (%) III, n (%) IV, n (%)
A Autoimmune cytopenia 24
(35.3%)
9
(13.2%)
10
(14.7%)
23
(33.8%)
2
2.9%9)
B Enteropathy/inflammatory bowel disease 13
(19.1%)
5
(7.4%)
10
(14.7%)
31
(45.6%)
9
(13.2%)
C Lymphoproliferation/splenomegaly/hepatomegaly 13
(19.1%)
14
(20.6%)
23
(33.8%)
17
(25.0%)
1
(1.5%)
D Parenchymal lung disease/lymphocytic interstitial
pneumonia/granulomatous lymphocytic Interstitial
lung disease
28
(41.2%)
4
(5.9%)
7
(10.3%)
23
(33.8%)
6
(8.8%)
E Skin or eye manifestations/eczema, uveitis, alopecia,
vitiligo, other
43
(63.2%)
4
(5.9%)
11
(16.2%)
9
(13.2%)
1
(1.5%)
F Endocrinopathy/insulin-dependent diabetes mellitus,
thyroiditis, other
50
(73.5%)
5
(7.4%)
1
(1.5%)
10
(14.7%)
2
(2.9%)
G Arthritis/other musculoskeletal 50
(73.5%)
4
(5.9%)
4
(5.9%)
9
(13.2%)
1
(1.5%)
H Autoimmune hepatitis/cholangitis/pancreatitis 55
(80.9%)
8
(11.8%)
2
(2.9%)
3
(4.4%)
0
(0%)
I Glomerulonephritis/nephropathy, tubulopathy 56
(82.4%)
2
(2.9%)
5
(7.4%)
2
(2.9%)
3
(4.4.%)
J Neurologic manifestations 53
(77.9%)
1
(1.5%)
2
(2.9%)
6
(7.4%)
7
(10.3%)
K Failure to thrive/malabsorption, wasting 19
(27.9%)
11
(16.2%)
13
(19.1%)
22
(32.4%)
3
(4.4%)
L Severe infections/opportunistic (excluding chronic
infestation)
18
(26.5%)
6
(8.8%)
22
(32.4%)
15
(22.1%)
7
(10.3%)
Other factors and symptoms (will multiply or add to
the score),§,k,#,{
M Karnofsky/Lansky scale (%) Median, 80%; range, 30%-100%
N Hospitalization (% 5 d/100 d; including day clinic
stays, excluding intensive care unit)
Median, 5%; range, 0%-100%
O Mechanical ventilation or other ICU measures (% 5 d/
100 d)
Median, 0%; range, 0%-10%
P Immunoglobulin substitution therapy (please read
comment for scoring)§
10
(14.7%)
5
(7.4%)
53
(77.9%)
Q Any relevant chronic or recurring infestation/infection
(eg, Norovirus, Epstein-Barr virus)k
29
(43.3%)
9
(13.4%)
18
(26.9%)
9
(13.4%)
2
(3.0%)
R Any other organ dysfunction/malady (eg,
cardiomyopathy, kidney failure){
39
(58.4%)
4
(6.0%)
11
(14.5%)
4
(6.0%)
9
(13.4%)
S Nutrition/dietary status and habits (please read
comment for scoring)#
27
(40.3%)
10
(14.9%)
12
(17.9%)
13
(19.4%)
5
(7.5%)
Z Malignancy, lymphoma (separately noted, not added to
score)
No, 73 (96.1%) Yes, 3 (3.9%)
IDDA score calculated as follows: IDDA 5 (A 1 B 1 C 1 D 1 E 1 F 1 G 1 H 1 I 1 J 1 K 1 L)/(M/150) 1 if (N < 40; N30.1; 4) 1 if (O < 10;
O30,8; 8)1 P 1 Q 1 R 1 S
ICU, Intensive care unit.
*Grading: 0 5 absent, inactive; 1 5 mild, transient, not requiring treatment; 2 5 moderate, intermittent therapy needed; 3 5 severe, continuous therapy needed; 4 5 life-
threatening, refractory, irreversible.
The number and percentage of the 68 patients with available complete IDDA scores at their worst clinical condition (episode, phase) are shown to depict the natural presentation
of the disease, whereas qualitative organ involvement (yes/no) known from the other 8 patients is not included here.
Use age-specific Karnofsky or Lansky performance scales (0%-100%; see Karnofsky and Burchenal22 and Lansky et al23).
§Values represent the following: 0 5 no; 2 5 sporadic; 3 (intravenous) 5 regularly intravenous immunoglobulin; 3 (subcutaneous) 5 regularly subcutaneous immunoglobulin.
kValues represent the following: 05 no; 15 asymptomatic infestation; 25 oligosymptomatic recurring infection; 35 recurring symptomatic infection requiring on/off treatment;
4 5 chronic infection requiring permanent treatment or refractory infection; only score one (worst) infection if more microbial agents are relevant.
#Values represent the following: 0 5 no organopathy; 1 5 mild transient dysfunction; 2 5 chronic mild dysfunction; 3 5 moderate-to-severe dysfunction; 4 5 clinically
compromising dysfunction requiring treatment or replacement therapy; only score 1 (worst) if more organs are involved.
{Values represent the following: 0 5 normal; 1 5 modified, disease-adjusted; 2 5 part-formula, medically advised; 3 5 tube feeding, full-formula, partial parenteral nutrition
(irregularly); 4 5 total parenteral nutrition.
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FIG 3. IDDA scores of patients with LRBA deficiency under conventional
treatment or undergoing HSCT. The longitudinal changes of the disease
activity, as measured by the IDDA scoring method at multiple time points
per patient (1-10; median, 2), is shown for 51 conventionally treated
patients (A) and 13 patients who received a transplant (B) over the time
span of their follow-up during which IDDA scores could be obtained.
IDDA scores before and after HSCT were available for only 13 of 24 patients
who underwent HSCT. The triangle indicates the time point of HSCT; in 6 of
13 patients, the first IDDA scores were measured immediately before HSCT.
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rated in 16 of 17 HSCT survivors (Fig 5, A). In a 7-year-old
patient who received a transplant in 2019, new neurologic
symptoms (absence seizures) and cytopenia were observed
4.5 months after HCST, although the patient’s IDDA score
also decreased after transplantation (patient 9 in Table E2).Characteristics and disease courses of patients with
LRBA deficiency under conventional
immunosuppressive treatment
In all, 52 patients (68.4%) did not undergo transplantation. Of
these 52 patients, 5 (aged 5, 8, 11, 21, and 37 years) were
identified through family screening and presented with either verymild or mild symptoms (intermittent cough or mild lymphopenia,
mild thrombocytopenia, urinary tract infection, or mild sinusitis)
or were asymptomatic (n 5 2) and did not require immunosup-
pressive treatment. The genotype did not predict the severity of
the phenotype, as these patients’ siblings or unrelated patients
with the identical mutation showed highly variable disease
activity. Of the 52 patients (90.1%) who did not undergo HSCT,
47 received immunosuppressive treatment.
A total of 43 patients (82.7%) were reported as still living at the
time of the analysis. Nine patients (17.3%) died at amedian age of
17 years (range, 1.5-35 years; Fig 2, A and B). The causes of death
includedmultiorgan failure, respiratory failure, severe lung infec-
tion, and CNS hemorrhage (Table II). All deceased patients under
conventional treatment suffered from lung involvement (paren-
chymal lung disease, lymphocytic interstitial pneumonia, or
granulomatous-lymphocytic interstitial lung disease; P 5 .0025,
Fig 2, G), as observed in our HSCT cohort, and 77.8% of these
patients (7 of 9) died of respiratory failure or severe lung infec-
tions (Table II). The treatment of 47 patients who required immu-
nosuppression started at a median age of 5 years (range, 0-60
years) with a median follow-up of 5.3 years (range, 1-35 years;
Fig 2, A and B). Systemic steroids were administered in 39 of
47 patients (82.9%) who needed immunosuppression, 26 were
treated with sirolimus (55.3%), and 23 received abatacept
(48.9%; see Table E1). Nine patients received rituximab
(19.1%), 9 (19.1%) were administered mycophenolate mofetil,
7 (14.9%) were treated with cyclosporine, and 3 (6.4%) received
azathioprine (see Fig E3 in this article’s Online Repository at
www.jacionline.org). Other mAbs (adalimumab, tocilizumab, in-
fliximab) were used in 2 patients (4.3%). Five patients did not
receive treatment (9.6%).
One aim in conducting this study was to assess disease activity
under different treatment modalities. The median current IDDA
score of living patients who did not undergo HSCT was 20.8
(range, 0-54.9), which is significantly higher than that of HSCT
survivors (median score of 6.3, range, 0-29.5; P 5 .005; Table I
and Fig 2, C). The patients’ IDDA scores varied over time (Fig
3, A), indicating that the overall disease progression could not
be prevented by immunosuppression alone. As more than 1
immunosuppressive agent was administered simultaneously in
many patients, the direct effects of single drugs could not always
be determined in this retrospective study. Patients (n 5 47) who
received only conventional treatment underwent 112 scored treat-
ment phases, with a median of 2 per patient (range, 1-10; Fig 4, A
and see Fig E3). Treatment with abatacept or sirolimus was asso-
ciated with significantly lower IDDA scores than was treatment
with glucocorticosteroids; the latter was associated with the high-
est disease activity in this cohort. Even when these scores were
compared with those of symptomatic patients who did not have
therapy-requiring autoimmunity (IgG replacement only), the pa-
tients who received abatacept had significantly lower IDDA
scores (P 5 .0375; Fig 4, A). Patients who received no treatment
and were identified as LRBA-deficient in the family screening,
showed the lowest disease activity, as theywere either asymptom-
atic or displayed very mild symptoms.
Abatacept was administered to 23 patients of our cohort, with a
follow-up of 400 patient-months (range, 0.1-5 years). No
immunosuppression-associated malignancy occurred in our
cohort, and no side effects were reported apart from newly
developed eczema in 2 patients after the initiation of abatacept.
IDDA scores decreased significantly in 14 patients who were
IG
 on
ly 
Ste
roi
ds
Sir
oli
mu
s 
Rit
ux
im
ab
Az
ath
iop
rin
Hy
dro
xy
ch
lor
oq
uin
Ab
ata
ce
pt 
No
 tre
atm
en
t0
20
40
60
80
100
IDDA Score per treatment phase 
ID
DA
  S
co
re
pre
 Ab
ata
ce
pt
po
st 
Ab
ata
ce
pt
0
50
100
ID
DA
 s
co
re
IDDA score pre/post Abatacept
pre
-H
SC
T
po
st-
HS
CT
0
50
100
ID
DA
 s
co
re
IDDA score pre/post HSCT 
A
B C
FIG 4. IDDA scores of patients with LRBA deficiency under various single immunosuppressive drug
regimens or before and after targeted treatment or HSCT. A, IDDA scores were measured (as described in
the Results section and in Table III) for 9 patients under immunoglobulin treatment only (IG, n5 9; first col-
umn from left to right); treatment with glucocorticosteroids (steroids, n5 35), sirolimus (n5 20), rituximab
(n5 7), azathioprine (n5 2), hydroxychloroquine (n5 7), or abatacept (n5 25); or no treatment (n57; with
very mild or no symptoms in patients identified mostly through family screening). Treatment with abata-
cept was associated with significantly lower IDDA scores than was treatment with steroids or even with
immunoglobulin therapy only (P 5 .0001 and P 5 .0375, respectively). Similarly, treatment courses with si-
rolimus were associated with lower IDDA scores than was treatment with steroids (P 5 .0296). Error bars
indicate mean and SE. B, IDDA scores in patients before and after abatacept monotherapy (n 5 14; P 5
.0039). C, IDDA scores of surviving patients before and after HSCT (n 5 13; P 5 .0002).
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
TESCH ET AL 9under no or different immunosuppressive treatment after the
initiation of abatacept only: the median IDDA score before the
initiation of abatacept was 34 (range, 9-57), and it decreased to
18.5 under abatacept (range, 4.8-45.2; P5 .0039; Fig 4, B). Aba-
tacept had effects on different, organ-specific, LRBA deficiency–
related symptoms (scored as 0-4, depicted in Fig 5, B). The
response to this treatment was not universal, as 3 patients (9,
10, and 13) showed neither a decrease in disease activity in
different organ systems nor an amelioration of signs of autoimmu-
nity and immune dysregulation. In 1 patient (12,) only autoim-
mune cytopenia could be resolved, but lymphoproliferation,
parenchymal lung disease, endocrinopathy, failure to thrive, and
severe infections were refractory to abatacept. All of the other
10 patients (71.4%), however, showed a good general response
to abatacept, with an amelioration of almost all symptoms (Fig
5, B). A combined treatment with sirolimus and abatacept was re-
ported in 1 patient only (follow-up for 1 year); this combined
treatment showed good effects, especially on parenchymal lung
disease. In our cohort, abatacept was, furthermore, combined
with several other drugs, such as nivaquine, mycophenolatemofetil, and adalimumab, all of which ameliorated LRBA-
related symptoms. No increase in the susceptibility to infections
or malignancy was observed.
The effects of sirolimus on different organ-specific, LRBA
deficiency–related symptoms (scored as 0-4) in 16 patients are
depicted in Fig 5, C. Initiation of sirolimus ameliorated enterop-
athy in 57.0% of patients, whereas parenchymal lung disease
improved in 38.5%. Amore noticeable effect was seen on autoim-
mune cytopenia; this symptom completely resolved in 37.5% of
patients and improved in an additional 25%. The symptoms of
4 of 5 patients (80%) with neurologic manifestations could be
ameliorated by sirolimus. The failure to thrive and malabsorption
improved in 29.4%, and fewer or less severe infections were noted
in 35.3% of the patients.DISCUSSION
This international, multicenter study provides a comprehen-
sive, retrospective analysis of the long-term clinical courses of
patients with LRBA deficiency treated with various conventional
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FIG 5. Graded organ involvement in patients with LRBA deficiency before and after HSCT, abatacept, or
sirolimus therapy. The organ involvement was graded by the caring physicians from 0 (not affected), 1
(mild, transient, not requiring treatment), 2 (moderate, intermittent immunosuppressive therapy needed),
or 3 (severe, continuous immunosuppression required), to 4 (refractory, life-threatening) before and after 3
different treatment interventions and is shown as a heatmap in column pairs per patient for HSCT (A),
monotherapy with abatacept (B), and monotherapy with sirolimus (C). The patient numbers above the col-
umn pairs do not correspond to the patient identification number in the cohort as listed in Table E1. AI,
Autoimmune; GLILD, granulomatous lymphocytic interstitial lung disease; IBD, inflammatory bowel
disease; IDDM, insulin-dependent diabetes mellitus; LIP, lymphocytic interstitial pneumonia.
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evaluated by the newly introduced IDDA scoring method.
Doctors treating patients with LRBA deficiency are often
uncertain whether and when to proceed with HSCTon account ofthe clinical variability of the disease. The lack of genotype-
phenotype correlations2,4,5 and a reportedly rather high TRM
observed in these patients as compared with that in patients
with other inborn errors, despite the potential for good outcomes
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the number of patients with a follow-up exceeding 15 years after
the onset of symptoms is small, our results indicate that the long-
term survival probability in patients who did not receive a trans-
plant is comparable to that of patients who have undergone HSCT
so far. However, HSCT survivors showed a stable remission of
LRBA deficiency–related symptoms and usually did not require
further immunosuppression. Like patients with the immunodysre-
gulation polyendocrinopathy enteropathy X-linked (IPEX) syn-
drome due to FOXP3 deficiency and defective Treg function,24
patients with LRBA deficiency receiving conventional treatment
had a higher disease burden throughout their lives and needed
more drugs.
The therapeutic dilemma of proceeding to HSCT in less pro-
found than severe combined immunodeficiencies25 (P-CIDs)
before clinical deterioration has been addressed in various
studies and disease entities, and different clinical scoring
scales have been proposed. In contrast to the morbidity mea-
sure of the ongoing P-CID study or the organ impairment
score of a recent IPEX study24,26 (see the Supplementary
Material), the IDDA score adds the graded involvement scores
of 10 organ systems known to be affected in LRBA deficiency
at a certain time point or interval and does not include a
correction for the patient age. Furthermore, extending the P-
CID or the IPEX score, physician-reported Karnofsky or Lan-
sky performance indices22,23 are used to multiply the IDDA
score, and the number of days of hospitalization, the need
for intensive or supportive care, the requirement of immuno-
globulin replacement therapy, nutritional support status, organ
insufficiency, and chronic infections also increase the score.
Together, consideration of all of these factors allows physi-
cians to depict the actual disease burden (eg, derived at 1
time point for a defined time frame). IDDA scoring can be
used for intraindividual longitudinal monitoring to facilitate
objective assessment and enable interindividual comparisons
(eg, in drug studies or multicenter trials) or during the regular
clinical assessment of a patient’s status as entered in a patient
registry. This study was not designed to correlate other immu-
nologic parameters (eg, immunoglobulin concentrations,
lymphocyte subsets, soluble IL-2 receptor level) with the dis-
ease activity or IDDA score.
All patients with residual LRBA protein expression were
still alive at the time of writing this publication and had a
lower median disease burden (IDDA score), whereas absent
protein expression was associated with a worse disease
outcome. Although many variants reported to yield residual
protein are compound heterozygous and located at the C-
terminus of the protein (including the DUF1088, BEACH, and
WD40 domains), other mutations with the same characteristics
lead to a complete absence of LRBA, again precluding a
genotype-phenotype correlation. Thus, quantification of pro-
tein expression should be used as an additional and relatively
simple tool to guide treatment decisions, and residual expres-
sion should be monitored over time.27 Patients with residual
LRBA expression appeared to be at lower risk with less
requirement for intensive therapy, but the relatively small
number of such patients precludes general treatment recom-
mendations for this subcohort with regard to immunosuppres-
sion or HSCT.
Among all immunosuppressive drugs reportedly used, abata-
cept and sirolimus were clearly favored over other conventionaltreatment modalities in our cohort with regard to the amelio-
ration of symptoms and the IDDA score. The response to
targeted treatment with abatacept was organ unspecific but not
universal, although a significant decrease in disease activity as
measured by the IDDA score could be achieved in the majority
of patients. Combinations of abatacept with sirolimus and other
immunosuppressive drugs and mAbs might act synergistically
in refractory courses, and they were successfully used in
selected patients in the present study without increasing the
patients’ susceptibility to infections or malignancy. However,
the data on these combinations are still too preliminary to draw
conclusions.
The rate of HSCT-related mortality in our cohort of 24
patients, who underwent transplantation between 2005 and
2019 and were in part (n 5 12) included in our previous
study,8 was relatively high (29.2%). Relapse due to rejection
was observed in 1 patient. The fact that many patients received
a transplant before their diagnosis of LRBA deficiency had
been made, and the fact that the disease of 3 of 7 deceased pa-
tients was not diagnosed until after death, could partially
explain the similarly high TRM observed in our current study.
In these patients HSCT might have been conducted as a last
resort after the development of many organ complications,
which reduced the chances of successful HSCT. The HSCT
outcome in cases of LRBA deficiency apparently improved
over the years, most probably owing to the concurrent increase
in knowledge about the disease. We observed that only 1 of 10
patients who received a transplant had died after the transplan-
tation procedures that were performed after 2015; in addition,
7 patients with LRBA deficiency of a Turkish cohort who
received a transplant were recently reported (but not included
in the present study) to be well and still living, with a median
follow-up of 2 years after their transplantation procedure.3
These findings suggest that the conclusions from early reports
suggesting that LRBA deficiency per se was associated with a
high TRM should be revised. In the current study, the trans-
plantation outcome was clearly better in patients with lower
IDDA scores (100% survival in patients with an IDDA score
of <15) and thus better pre-HSCT clinical conditions. Lung
involvement could be ameliorated in a percentage of patients
under abatacept or sirolimus treatment and resolved in many
patients after HSCT (Fig 5), but patients with uncontrolled
pulmonary disease should be considered at highest risk. Our
findings indicate that doctors should strive to ameliorate the
clinical condition before transplantation in patients with higher
disease activity, especially in cases of lung involvement. This
goal might be achieved by using a ‘‘bridging’’ therapy with, for
example, abatacept, as was administered to 6 patients of our
cohort. The longitudinal monitoring results show that severe
phenotypes have no tendency to resolve entirely; instead,
they persist and, as in cases of CTLA4 insufficiency, even
progress or predispose the patient to malignancy.2-4,6,28 Taken
together, these findings call into question the prior recommen-
dations to consider HSCT only in cases of severe phenotypes
of LRBA deficiency8 and instead indicate that transplantation
should be considered before the disease progresses.
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12 TESCH ET ALClinical implications: This international, retrospective study on
76 patients with LRBA deficiency with long-term follow-up de-
tected the best outcomes in patients with residual protein
expression, low pre-HSCT disease burden, absent lung involve-
ment, or targeted therapy.
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